The U.S. Food and Drug Administration granted fast track designation on July 22 to DB-1310, a next-generation HER3-targeting antibody-drug conjugate (ADC) for patients with advanced, unresectable non-small cell lung cancer (NSCLC) harboring specific EGFR mutations who have progressed on prior therapy. In breast cancer research, the HER2-targeted bispecific antibody TQB2930 combined with chemotherapy showed responses and an acceptable safety profile in patients with HER2-positive metastatic breast cancer who had undergone at least two prior HER2-targeted treatments. Additionally, real-world data support the use of tucatinib-based treatments in HER2-positive metastatic breast cancer. The SERENA-6 phase 3 trial demonstrated that switching to camizestrant with a CDK4/6 inhibitor after detection of ESR1 mutations, but before disease progression, significantly extended progression-free survival in advanced breast cancer patients. Another combination, dalpiciclib plus pyrotinib and endocrine therapy, exhibited efficacy in ER-positive, HER2-positive advanced breast cancer. In sarcoma treatment, anlotinib combined with toripalimab showed antitumor activity in advanced soft tissue and bone sarcomas. For NSCLC, a phase 3 evaluation of sigvotatug vedotin is ongoing in pretreated nonsquamous NSCLC patients. Verastem Oncology and its partner GenFleet Therapeutics announced a late-breaking abstract on GFH375 (VS-7375) for advanced NSCLC at the IASLC 2025 World Conference on Lung Cancer, highlighting developments in lung cancer therapies in China.